Advanced Oncotherapy PLC Appointment of Nominated Adviser and Joint Broker (7572O)
February 01 2019 - 1:00AM
UK Regulatory
TIDMAVO
RNS Number : 7572O
Advanced Oncotherapy PLC
01 February 2019
1 February 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Appointment of Nominated Adviser and Joint Broker
Advanced Oncotherapy (AIM: AVO), the developer of a
next-generation proton therapy system for cancer treatment, is
pleased to announce the appointment of Allenby Capital Limited as
the Company's nominated adviser and joint broker with immediate
effect.
For further information, please contact:
Advanced Oncotherapy Plc Tel: +44 (0) 20 3617 8728
Dr. Michael Sinclair, Executive www.avoplc.com
Chairman
Nicolas Serandour, CEO
Allenby Capital Limited (Nominated Tel: +44 (0) 20 3328 5656
Adviser & Joint Broker)
Nick Athanas / Liz Kirchner / Nicholas
Chambers
Stifel Nicolaus Europe (Joint Broker) Tel: +44 (0) 20 7710 7600
Jonathan Senior
Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 8780 avo@walbrookpr.com
Paul McManus / Anna Dunphy
Mob: +44 (0) 7980 541 893
Mob: +44 (0) 7876 741 001
About Advanced Oncotherapy Plc
Advanced Oncotherapy is a provider of particle therapy in the
treatment of cancer, which harnesses the very best in modern
technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva,
focuses on the development of a proprietary proton accelerator -
LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates
protons to the energy levels achieved in legacy machines but in a
compact and truly modular unit, offering significant cost
advantages. LIGHT also delivers proton beams in a way that
facilitates greater precision and electronic control, which are not
achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology, offering better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton or particle therapy and
actively seeks working relationships with providers of these
innovative technologies. Through these relationships, the Company
will remain the prime provider of cutting edge, cost-effective
systems for particle therapy.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPEAPFFDLANEFF
(END) Dow Jones Newswires
February 01, 2019 02:00 ET (07:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2023 to Apr 2024